Caribou Biosciences (CRBU) Asset Writedowns and Impairment (2025)
Caribou Biosciences (CRBU) reported Asset Writedowns and Impairment of $2.2 million for Q2 2025, down 76.09% quarter-over-quarter from $9.2 million in Q1 2025.
Caribou Biosciences (CRBU) Asset Writedowns and Impairment (2025) Analysis & Trends
Caribou Biosciences (CRBU) has 1 years of Asset Writedowns and Impairment data on file, last reported at $2.2 million in Q2 2025.
- Asset Writedowns and Impairment for Q2 2025 came in at $2.2 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $2.2 million (changed N/A YoY), and the FY2025 annual result was $12.1 million, changed N/A from the prior year.
- Asset Writedowns and Impairment fell to $2.2 million in Q2 2025 per CRBU's latest filing, from $9.2 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $9.2 million in Q1 2025 and troughed at $2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Caribou Biosciences | 156.73 Mn | 39.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2.20 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Mar 31, 2025 | 9.20 Mn |